{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Zitomersky N"],"funding":["NIDDK NIH HHS"],"pagination":["261-271"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10883602"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["78(2)"],"pubmed_abstract":["<h4>Background</h4>Infliximab (IFX) use is limited by loss of response often due to the development of anti-IFX antibodies and low drug levels.<h4>Methods</h4>We performed a single center prospective observational cohort study of pediatric and young adult subjects with inflammatory bowel disease (IBD) on IFX with over 3 years of follow-up. Infliximab levels (IFXL) and antibodies to infliximab (ATI) were measured throughout the study. Subjects were followed until IFX was discontinued.<h4>Results</h4>We enrolled 219 subjects with IBD (184: Crohn's disease; 33: Ulcerative colitis; and 2 Indeterminant colitis; 84 female, median age 14.4 years, 37% on concomitant immunomodulator). Nine hundred and nineteen serum samples (mean 4.2 ± 2.1 per patient) were tested for IFXL and ATI. During the study"],"journal":["Journal of pediatric gastroenterology and nutrition"],"pubmed_title":["Anti-infliximab antibodies and low infliximab levels correlate with drug discontinuation in pediatric inflammatory bowel disease."],"pmcid":["PMC10883602"],"funding_grant_id":["K23 DK119584","T32 DK007760","P30 DK034854"],"pubmed_authors":["Chi L","Silvester JA","Zitomersky N","Papamichael K","Snapper SB","Liu E","Bray KR","Bousvaros A","Cheifetz AS"],"additional_accession":[]},"is_claimable":false,"name":"Anti-infliximab antibodies and low infliximab levels correlate with drug discontinuation in pediatric inflammatory bowel disease.","description":"<h4>Background</h4>Infliximab (IFX) use is limited by loss of response often due to the development of anti-IFX antibodies and low drug levels.<h4>Methods</h4>We performed a single center prospective observational cohort study of pediatric and young adult subjects with inflammatory bowel disease (IBD) on IFX with over 3 years of follow-up. Infliximab levels (IFXL) and antibodies to infliximab (ATI) were measured throughout the study. Subjects were followed until IFX was discontinued.<h4>Results</h4>We enrolled 219 subjects with IBD (184: Crohn's disease; 33: Ulcerative colitis; and 2 Indeterminant colitis; 84 female, median age 14.4 years, 37% on concomitant immunomodulator). Nine hundred and nineteen serum samples (mean 4.2 ± 2.1 per patient) were tested for IFXL and ATI. During the study","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Feb","modification":"2025-04-21T23:54:16.975Z","creation":"2025-04-05T19:20:12.142Z"},"accession":"S-EPMC10883602","cross_references":{"pubmed":["38374555"],"doi":["10.1002/jpn3.12074"]}}